Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Esanex

Status and phase: Completed; Phase 1

Conditions: Hematologic Neoplasms

Treatments: Drug: SNX-5422

Study type: Interventional

Funder types: Industry

Identifiers

NCT00595686

SNX-5422-CLN1-002

B1311002

Details and patient eligibility

About

Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Enrollment: 25 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• >18 years old
• Karnofsky performance status > 60
• confirmed hematological malignancy
• refractory to available therapy or for which no therapy is available
• adequate hepatic, renal and hematological function

Exclusion criteria

• CNS malignancy
• at risk for prolonged QT interval
• significant GI/liver disease
• other serious concurrent illness or medical condition

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

Single Arm

Experimental group

Treatment:

Drug: SNX-5422